Zobrazeno 1 - 10 of 101 pro vyhledávání: '"Morelli MF"'
1
Akademický článek
Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program
Autor: Quaglino P, Ascierto PA, Consoli F, Queirolo P, Spagnolo F, Morelli MF, Berardi R, Chiarion-Sileni V, Tucci M, Troiani T, Melotti B, Rossi E, Mandala M, Rinaldi G, Marcon IG, Pizzuti M, Del Vecchio M
Publikováno v: Cancer Management and Research, Vol Volume 15, Pp 1271-1281 (2023)
Pietro Quaglino,1 Paolo A Ascierto,2 Francesca Consoli,3 Paola Queirolo,4 Francesco Spagnolo,5 Maria Francesca Morelli,6 Rossana Berardi,7 Vanna Chiarion-Sileni,8 Marco Tucci,9 Teresa Troiani,10 Barbara Melotti,11 Ernesto Rossi,12 Mario Mandala,13 Ga
Externí odkaz: https://doaj.org/article/61e573f959ce4c9193d56a436410e730
Zobrazit plný text záznamu
2
Akademický článek
Survival of Patients with Metastatic Melanoma Treated with Ipilimumab after PD-1 Inhibitors: A Single-Center Real-World Study.
Autor: Verkhovskaia S; Department of Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Falcone R; Department of Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Di Pietro FR; Department of Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Carbone ML; Clinical Trial Center, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Samela T; Epidemiology Units, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Perez M; Department of Histopathology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Poti G; Department of Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Morelli MF; Department of Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Zappalà AR; Department of Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Di Rocco ZC; Department of Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Morese R; Department of Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Piesco G; Department of Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Chesi P; Department of Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Marchetti P; Department of Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Abeni D; Epidemiology Units, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Failla CM; Experimental Immunology Laboratory, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., De Galitiis F; Department of Oncology, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy.
Publikováno v: Cancers [Cancers (Basel)] 2024 Oct 04; Vol. 16 (19). Date of Electronic Publication: 2024 Oct 04.
Zobrazit plný text záznamu
3
Akademický článek
Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience.
Autor: Di Pietro FR; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Rome, Italy., Marinelli D; Department of Experimental Medicine, Sapienza University, Rome, Italy., Verkhovskaia S; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Rome, Italy., Poti G; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Rome, Italy., Falcone R; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Rome, Italy., Carbone ML; Clinical Trial Center, IDI-IRCCS, Rome, Italy. marialuigia.carbone@idi.it., Morelli MF; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Rome, Italy., Zappalà AR; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Rome, Italy., Di Rocco ZC; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Rome, Italy., Morese R; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Rome, Italy., Piesco G; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Rome, Italy., Chesi P; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Rome, Italy., Marchetti P; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Rome, Italy., Failla CM; Experimental Immunology Laboratory, IDI-IRCCS, Rome, Italy., De Galitiis F; Department of Oncology and Dermatological Oncology, IDI-IRCCS, Rome, Italy.
Publikováno v: BMC cancer [BMC Cancer] 2024 Oct 01; Vol. 24 (1), pp. 1220. Date of Electronic Publication: 2024 Oct 01.
Zobrazit plný text záznamu
4
Akademický článek
Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients.
Autor: Di Pietro FR; Oncology and Dermato-oncology Department, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy., Verkhovskaia S; Oncology and Dermato-oncology Department, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy., Falcone R; Oncology and Dermato-oncology Department, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy., Poti G; Oncology and Dermato-oncology Department, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy., Carbone ML; Clinical Trial Center, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy., Morelli MF; Oncology and Dermato-oncology Department, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy., Zappalà AR; Oncology and Dermato-oncology Department, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy., Morese R; Oncology and Dermato-oncology Department, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy., Di Rocco ZC; Oncology and Dermato-oncology Department, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy., Piesco G; Oncology and Dermato-oncology Department, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy., Chesi P; Oncology and Dermato-oncology Department, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy., Failla CM; Laboratory of Experimental Immunology, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy., Marchetti P; Scientific Direction, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy., De Galitiis F; Oncology and Dermato-oncology Department, Istituto Dermopatico dell'Immacolata (IDI)-IRCCS, Rome, Italy.
Publikováno v: Frontiers in oncology [Front Oncol] 2024 Aug 01; Vol. 14, pp. 1437325. Date of Electronic Publication: 2024 Aug 01 (Print Publication: 2024).
Zobrazit plný text záznamu
5
Akademický článek
Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center.
Autor: Falcone R; Department of Oncology, IDI-IRCCS, 00167 Rome, Italy., Verkhovskaia S; Department of Oncology, IDI-IRCCS, 00167 Rome, Italy., Di Pietro FR; Department of Oncology, IDI-IRCCS, 00167 Rome, Italy., Poti G; Department of Oncology, IDI-IRCCS, 00167 Rome, Italy., Samela T; Department of Oncology, IDI-IRCCS, 00167 Rome, Italy., Carbone ML; Experimental Immunology Laboratory, IDI-IRCCS, 00167 Rome, Italy., Morelli MF; Department of Oncology, IDI-IRCCS, 00167 Rome, Italy., Zappalà AR; Department of Oncology, IDI-IRCCS, 00167 Rome, Italy., di Rocco ZC; Department of Oncology, IDI-IRCCS, 00167 Rome, Italy., Morese R; Department of Oncology, IDI-IRCCS, 00167 Rome, Italy., Piesco G; Department of Oncology, IDI-IRCCS, 00167 Rome, Italy., Marchetti P; Department of Oncology, IDI-IRCCS, 00167 Rome, Italy., Failla CM; Experimental Immunology Laboratory, IDI-IRCCS, 00167 Rome, Italy., De Galitiis F; Department of Oncology, IDI-IRCCS, 00167 Rome, Italy.
Publikováno v: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Jan 22; Vol. 31 (1), pp. 588-597. Date of Electronic Publication: 2024 Jan 22.
Zobrazit plný text záznamu
6
Akademický článek
Characteristics of Real-World Patients with High-Risk BRAF V600E/K -Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program.
Autor: Quaglino P; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy., Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Consoli F; Department of Oncology, ASST Spedali Civili, Brescia, Italy., Queirolo P; Oncology Division, Policlinico San Martino IRCCS, Genova, Italy, and Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy., Spagnolo F; Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Morelli MF; Department of Oncology and Dermatological Oncology, Istituto Dermopatico dell'Immacola, Rome, Italy., Berardi R; Università Politecnica delle Marche - Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy., Chiarion-Sileni V; Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Tucci M; Medical Oncology Unit, Department of Interdisciplinary Medicine, University of Bari 'Aldo Moro', Bari, Italy., Troiani T; Faculty of Medicine, Second University of Naples, Naples, Italy., Melotti B; Medical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Rossi E; Medical Oncology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy., Mandala M; Division of Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy, and University of Perugia, Perugia, Italy., Rinaldi G; UOC Oncologia Medica Aoup Paolo Giaccone, Palermo, Italy., Marcon IG; Novartis Farma S.p.A, Milan, Italy., Pizzuti M; Novartis Farma S.p.A, Milan, Italy., Del Vecchio M; Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v: Cancer management and research [Cancer Manag Res] 2023 Nov 11; Vol. 15, pp. 1271-1281. Date of Electronic Publication: 2023 Nov 11 (Print Publication: 2023).
Zobrazit plný text záznamu
7
Akademický článek
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study.
Autor: Bersanelli M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Verzoni E; SS.Oncologia Genitourinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Cortellini A; Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy.; Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, UK., Giusti R; Medical Oncology Unit, Azienda Ospedaliero-Universitaria Sant'Andrea, Roma, Italy., Calvetti L; Department of Oncology, San Bortolo General Hospital, Unità Locale Socio-Sanitaria (ULSS)8 Berica, Vicenza, Italy., Ermacora P; Dipartimento di Oncologia, Presidio Ospedaliero Universitario Santa Maria della Misericordia, Azienda Sanitaria Universitaria Integrata Friuli Centrale, Udine, Italy., Di Napoli M; Department of Uro Gynecological Oncology, Istituto Nazionale dei Tumori IRCCS Fondazione G. Pascale, Napoli, Italy., Catino A; Medical Thoracic Oncology Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Guadalupi V; SS.Oncologia Genitourinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Guaitoli G; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy., Scotti V; SODc Radioterapia Oncologica, DAI Oncologia, AOU Careggi, Firenze, Italy., Mazzoni F; Oncology Unit, Careggi University Hospital, Firenze, Italy., Veccia A; Medical Oncology, Santa Chiara Hospital, Trento, Italy., Guglielmini PF; S.C. Oncologia, AO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy., Perrone F; Medical Oncology Unit, University Hospital of Parma, Parma, Italy., Maruzzo M; Oncologia Medica 1, Dipartimento di Oncologia, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy., Rossi E; Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy., Casadei C; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Montesarchio V; U.O.C. Oncologia, Azienda Ospedaliera Specialistica dei Colli, Ospedale Monaldi, Napoli, Italy., Grossi F; Università degli Studi dell'Insubria, ASST dei Sette Laghi, Varese, Italy., Rizzo M; Oncologia Traslazionale, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy., Travagliato Liboria MG; Oncology Department, AO Ospedali Riuniti Palermo PO V. Cervello, Palermo, Italy., Mencoboni M; SSD Oncologia, Villa Scassi Hospital, ASL3 Regione Liguria, Genova, Italy., Zustovich F; UOC oncologia, AULSS 1 Dolomiti, Belluno, Italy., Fratino L; Oncologia Medica CRO di Aviano IRCCS, Aviano, Italy., Accettura C; Medical Oncology Unit, Ospedale Vito Fazzi, Lecce, Italy., Cinieri S; Medical Oncology Division and Breast Unit, Senatore Antonio Perrino Hospital, ASL Brindisi, Brindisi, Italy., Camerini A; Medical Oncology, Versilia Hospital - Azienda USL Toscana Nord Ovest, Lido di Camaiore, Italy., Sorarù M; Medical Oncology, Camposampiero Hospital, ULSS 6 Euganea, Padova, Italy., Zucali PA; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy., Ricciardi S; UOSD Pneumologia Oncologica, Az. Ospedal. San Camillo Forlanini, Roma, Italy., Russo A; Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy., Negrini G; Oncologia Medica, Ospedale Papa Giovanni XXIII, Bergamo, Italy., Banzi MC; Medical Oncology, Comprehensive Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy., Lacidogna G; Department of Oncology, University of Turin, Turin, Italy.; Medical Oncology, AO Ordine Mauriziano, Turin, Italy., Fornarini G; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Laera L; UOC di Oncologia e Oncoematologia Ente Ecclesiastico Ospedale Generale Regionale 'Miulli' Acquaviva delle Fonti (BA), Italy., Mucciarini C; Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy., Santoni M; UOC Oncologia, Ospedale Generale Provinciale di Macerata, ASUR Marche Area Vasta 3, Macerata, Italy., Mosillo C; Department of Oncology, Medical & Translational Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy., Bonetti A; Department of Oncology, Mater Salutis Hospital, Verona, Legnago, Italy., Longo L; UOSD Oncologia Area Sud Azienda AUSL Modena, Sassuolo (MO), Italy., Sartori D; Oncologia Dolo-Mirano, AULSS3 Veneziana, Venezia, Italy., Baldini E; Medical Oncology Unit, San Luca Hospital, Lucca, Italy., Guida M; Rare Tumors and Melanoma Unit, IRCCS Istituto dei Tumori 'Giovanni Paolo II', Bari, Italy., Iannopollo M; SOC Oncologia, Dipartimento di Oncologia, Azienda Usl Toscana Centro, Presidio Ospedaliero SS. Cosma e Damiano - Pescia e San Jacopo, Pistoia, Italy., Bordonaro R; Medical Oncology Unit, ARNAS Garibaldi, Catania, Italy., Morelli MF; U.O.C. Oncologia, Istituto Dermopatico dell'Immacolata IDI-IRCCS, Roma, Italy., Tagliaferri P; Department of Experimental and Clinical Medicine, Magna Græcia University, Catanzaro, Italy., Spada M; UOC Oncologia, Fondazione Istituto G. Giglio - C.da Pietrapollastra-Pisciotto SNC, Cefalù (PA), Italy., Ceribelli A; Department of Oncology, San Camillo De Lellis Hospital, Rieti, Italy., Silva RR; Medical Oncology, ASUR Marche, Area Vasta 2, Fabriano, Italy., Nolè F; Medical Oncology Division of Urogenital and Head & Neck Tumours IEO, European Institute of Oncology IRCCS, Milano, Italy., Beretta G; UOC Oncologia Medica, Ospedale Spirito Santo, Pescara, Italy., Giovanis P; UOC Oncologia, Ospedale Santa Maria del Prato, Feltre, AULSS1 Dolomiti, Feltre, Italy., Santini D; Oncologia Medica A, Policlinico Umberto 1, La Sapienza Università di Roma, Romaa, Italy., Luzi Fedeli S; Department of Medical Oncology, AOU Ospedali Riuniti, Presidio San Salvatore, Pesaro, Italy., Nanni O; Biostatistics and Clinical Research Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Maiello E; Department of Oncology, Fondazione 'Casa Sollievo della Sofferenza' IRCCS Hospital, San Giovanni Rotondo, Italy.; Federation of Italian Cooperative Oncology Groups (FICOG), Milan, Italy., Labianca R; Federation of Italian Cooperative Oncology Groups (FICOG), Milan, Italy.; Medical Oncology Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy., Pinto C; Medical Oncology, Comprehensive Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.; Federation of Italian Cooperative Oncology Groups (FICOG), Milan, Italy., Clemente A; Federation of Italian Cooperative Oncology Groups (FICOG), Milan, Italy., Tognetto M; Federation of Italian Cooperative Oncology Groups (FICOG), Milan, Italy., De Giorgi U; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.; Federation of Italian Cooperative Oncology Groups (FICOG), Milan, Italy., Pignata S; Department of Uro Gynecological Oncology, Istituto Nazionale dei Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.; Federation of Italian Cooperative Oncology Groups (FICOG), Milan, Italy., Di Maio M; Department of Oncology, University of Turin, Turin, Italy.; Medical Oncology, AO Ordine Mauriziano, Turin, Italy., Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Medicine and Surgery Department, University of Parma, Parma, Italy., Giannarelli D; Facility of Epidemiology & Biostatistics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
Publikováno v: EClinicalMedicine [EClinicalMedicine] 2023 Jun 29; Vol. 61, pp. 102044. Date of Electronic Publication: 2023 Jun 29 (Print Publication: 2023).
Zobrazit plný text záznamu
8
Akademický článek
The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study.
Autor: Del Vecchio M; Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy., Chiarion Sileni V; Veneto Institute of Oncology IOV-IRCCS, 35128 Padova, Italy., Quaglino P; Dermatology Clinic, Department of Medical Sciences, University of Turin, 10126 Turin, Italy., Rinaldi G; Aoup Paolo Giaccone Palermo, 90127 Palermo, Italy., Minisini A; Azienda Sanitaria Universitaria Del Friuli Centrale, 33100 Udine, Italy., Troiani T; Unit of Dermatology, University of Campania Luigi Vanvitelli, 80123 Naples, Italy., Consoli F; Medical Oncology, ASST Spedali Civili, 25123 Brescia, Italy., Sponghini A; AOU Maggiore della Carità, DIMET, Università del Piemonte Orientale, 28100 Novara, Italy., Banzi M; Presidio Ospedaliero Arcispedale S. Maria Nuova AUSL di Reggio Emilia-IRCCS, 42123 Reggio Emilia, Italy., Morelli MF; Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome, Italy., Palleschi D; Presidio Ospedaliero S. Maria di Ca' Foncello Azienda ULSS 2, Marca Trevigiana, 31100 Treviso, Italy., Rossi E; Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, 00168 Rome, Italy., Marconcini R; Presidio Ospedaliero S. Chiara, Azienda Ospedaliero Universitaria Pisana, 56100 Pisa, Italy., Depenni R; Department of Oncology and Hematology, University Hospital of Modena and Reggio Emilia, 41121 Modena, Italy., Carnevale-Schianca F; Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy., Marcon I; Novartis Farma S.p.A, 20154 Milan, Italy., Queirolo P; European Institute of Oncology-IRCCS, 20141 Milan, Italy.
Publikováno v: Cancers [Cancers (Basel)] 2023 Mar 26; Vol. 15 (7). Date of Electronic Publication: 2023 Mar 26.
Zobrazit plný text záznamu
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje